Literature DB >> 11431740

Temporal changes in insulin sensitivity following the development of acute liver failure secondary to acetaminophen.

S J Clark1, F Shojaee-Moradie, P Croos, P T Seed, A M Umpleby, J A Wendon, J Miell.   

Abstract

Insulin resistance in chronic liver disease (CLD) is well documented. This study investigated whether similar changes occur in acute liver failure (ALF). Patients with ALF (n = 10) were recruited within 72 hours of their peak prothrombin time (range 42-120 seconds). All patients were ventilated for encephalopathy (grade III-IV). Peripheral and endogenous insulin sensitivity were assessed by a hyperinsulinemic euglycemic clamp (Human Actrapid 1.5 mU/min/kg) with an infusion of D-[6,6-(2)H(2)] glucose. The clamp was performed on day 0 and then on day 7 and day 14. During the insulin infusion, the mean total peripheral glucose uptake (area under the curve [AUC]) was 1,422 (SD, 1,253), 2,244 (SD, 1,392), and 4,500 (SD, 1,120) micromol/kg on days 0, 7, and 14, respectively. Significant changes occurred from day 0 to 14 (day 14-day 0: 3,078 [95% CI, 1,798 to 4,359]; P =.001) and day 7 to 14 (day 14-day 7: 2,256 [95% CI, 923 to 3,589]; P =.001). No significant difference in endogenous glucose production was demonstrated over time. Mean peripheral insulin sensitivity altered over time, increasing from 0.09 (SD, 0.09) micromol/kg/min/mU/L on day 0 to 0.24 (SD, 0.16) on day 7 and 0.5 (SD, 0.1) on day 14. Significant changes occurred between days 0, 7, and 14 (day 7-day 0: 0.15 [95% CI, 0.04 to 0.26], P =.006; day 14-day 0: 0.4 [95% CI, 0.28 to 0.5], P =.001; day 14-day 7: 0.2 [95% CI, 0.12 to 0.38], P =.001). This study demonstrates that in ALF, impaired peripheral uptake of glucose occurs, peripheral insulin sensitivity being restored at 2 weeks in subjects who survived.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431740     DOI: 10.1053/jhep.2001.25514

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

Review 1.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Authors:  Tannaz Eslamparast; Sareh Eghtesad; Hossein Poustchi; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Olive oil consumption and non-alcoholic fatty liver disease.

Authors:  Nimer Assy; Faris Nassar; Gattas Nasser; Maria Grosovski
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

3.  Fulminant hepatic failure.

Authors:  Jelica Kurtovic; Stephen M Riordan; Roger Williams
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

4.  Acetaminophen: beyond pain and Fever-relieving.

Authors:  Eric R Blough; Miaozong Wu
Journal:  Front Pharmacol       Date:  2011-11-09       Impact factor: 5.810

5.  Expression Levels of GABA-A Receptor Subunit Alpha 3, Gabra3 and Lipoprotein Lipase, Lpl Are Associated with the Susceptibility to Acetaminophen-Induced Hepatotoxicity.

Authors:  Minjeong Kim; Jun-Won Yun; Kyeho Shin; Yejin Cho; Mijeong Yang; Ki Taek Nam; Kyung-Min Lim
Journal:  Biomol Ther (Seoul)       Date:  2017-03-01       Impact factor: 4.634

Review 6.  Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents.

Authors:  Ali Hashemi Kani; Seyed Moayed Alavian; Fahimeh Haghighatdoost; Leila Azadbakht
Journal:  Hepat Mon       Date:  2014-02-17       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.